PD-1/PD-L1 blockade is a breakthrough in cancer immunotherapy, and it has been trialed in a broad range of malignancies in the preclinical or clinical stage, including melanoma [6], Hodgkin’s lymphoma [7], breast cancer [8, 9], non-small cell lung cancer (NSCLC) [10], as well as hepatocellular carcinoma [11, 12]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.